With a YTD Return of 24.2% as of May 7, Alphabet Inc. (NASDAQ:GOOG) is included among the 10 Best Stocks to Buy to Beat the S&P 500. On May 7, Mizuho raised its price recommendation on Alphabet Inc. (NASDAQ:GOOG) to $460 from $420 and maintained an Outperform rating on the shares. The firm said Wall Street estimates […]
With a YTD Return of 24.2% as of May 7, Alphabet Inc. (NASDAQ:GOOG) is included among the 10 Best Stocks to Buy to Beat the S&P 500. On May 7, Mizuho raised its price recommendation on Alphabet Inc. (NASDAQ:GOOG) to $460 from $420 and maintained an Outperform rating on the shares. The firm said Wall Street estimates […]
Earnings Call Insights: TOMI Environmental Solutions (TOMZ) Q1 2026 Management view "Q1 2026 marked a healthy start to the year" and "Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025," CEO Halden Shane said, highlighting that "applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025" and that the company generated "positive operating ...
Earnings Call Insights: TOMI Environmental Solutions (TOMZ) Q1 2026 Management view "Q1 2026 marked a healthy start to the year" and "Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025," CEO Halden Shane said, highlighting that "applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025" and that the company generated "positive operating cash flow of $296,000." (Chairman & CEO Halden Shane) Management tied the quarter’s commercial cadence to backlog and recurring services, saying, "At year-end of 2025, TOMI reported $1.6 million in backlog, which grew by $0.5 million by the close of Q1 2026 and is currently at $2.2 million," and added, "At the end of quarter 1, TOMI received 440,000 annual purchase orders for recurring decontamination services with a leading global medical technology company." (Chairman & CEO Shane) On international commercialization, management said, "In February, we received official authorization from the U.K. Health and Safety Executive," "In March, we secured product authorization from the Dutch regulatory authority," and "this past week, we received notification of further approvals in Germany, Belgium, Denmark and Hungary." (Chairman & CEO Shane) The company announced a strategic transaction, stating, "On April 30, 2026, we executed a nonbinding letter of intent to merge with Carbonium Core, Inc.," and under the LOI, "Former stockholders would receive TOMI common stock equal to 19.99% of shares outstanding prior to the merger, along with shares of a newly created series of convertible preferred stock, implying an enterprise valuation of $120 million." (Chairman & CEO Shane) CFO David Vanston framed Q1 results and one-time comparability, saying, "Revenue for Q1 '26 was $1.6 million," "The net loss was $811,000 or $0.04 a share," and "Q1 '25 net loss included a nonrecurring employee retention credit of $535,000 and related interest of $83,000." (Chief Financial Officer David Vanston) C...
Earnings Call Insights: Vaxart (VXRT) Q1 2026 Management View “In the first quarter, we made meaningful progress advancing our clinical programs and preparing for key data milestones that we believe will help demonstrate the value of our oral vaccine platform.” (President, CEO & Director Steven Lo) “Specifically, our work during the first quarter was focused on the steps needed to disclose data fr...
Earnings Call Insights: Vaxart (VXRT) Q1 2026 Management View “In the first quarter, we made meaningful progress advancing our clinical programs and preparing for key data milestones that we believe will help demonstrate the value of our oral vaccine platform.” (President, CEO & Director Steven Lo) “Specifically, our work during the first quarter was focused on the steps needed to disclose data from the 400-person sentinel cohort of our Phase IIb COVID-19 trial.” (President, CEO & Director Lo) “To further strengthen our Board and add clinical and strategic oversight, we were pleased to welcome Dr. James Breitmeyer to our Board of Directors in April.” (President, CEO & Director Lo) “On the operational side, we completed our headquarters move in April, consolidating and reducing our footprint and also established a $25 million share purchase agreement with Lincoln Park Capital. No shares have been sold to date, and the use of this purchase agreement is subject to the company's discretion.” (President, CEO & Director Lo) “Vaxart management is currently blinded to the results and has not reviewed the data.” (Chief Medical Officer James Cummings) “More definitive insights are expected to come from our main cohort of approximately 5,000 participants, which is designed and powered to evaluate relative efficacy and safety.” (Chief Medical Officer Cummings) “We are prepared to initiate our next clinical trial in 2026, depending on a partnership or the receipt of other funding.” (Senior VP & Chief Scientific Officer Sean Tucker) “Vaxart ended the first quarter with cash, cash equivalents and short-term investments of $61 million.” (CFO, Principal Accounting Officer & Principal Financial Officer Jeroen Grasman) Outlook “While we are still aiming to release the top line results in Q2, it's important to remember that we are working with the contractual partner, and we're not in full control of that timing.” (Chief Medical Officer Cummings) “We anticipate the primary efficacy and...